MAP2K7 and cancer: Combination therapy of MEK inhibitor PD98059 and anti-diabetic drug Rosiglitazone caused invasive and spreading cancer cells to transform into post-mitotic adipocytes, which inhibited the invasion of the primary tumor and the development of metastases [77].